PMID- 27514640
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20180618
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 23
IP  - 7
DP  - 2017 Oct
TI  - Factors Influencing ACT After Intravenous Bolus Administration of 100 IU/kg of 
      Unfractionated Heparin During Cardiac Catheterization in Children.
PG  - 740-747
LID - 10.1177/1076029616660761 [doi]
AB  - Anticoagulation using intravenous bolus administration of unfractionated heparin 
      (UFH) aims to prevent thromboembolic complications in children undergoing cardiac 
      catheterization (CC). Optimal UFH dosage is needed to reduce bleeding 
      complications. We analyzed the effect of bolus UFH on activated clotting time 
      (ACT) in children undergoing CC focusing on age-dependent, anesthesia-related, or 
      disease-related influencing factors. This retrospective single-center study of 
      183 pediatric patients receiving UFH during CC analyzed ACT measured at the end 
      of CC. After bolus administration of 100 IU UFH/kg body weight, ACT values 
      between 105 and 488 seconds were reached. Seventy-two percent were within target 
      level of 160 to 240 seconds. Age-dependent differences were not obtained ( P = 
      .407). The ACT values were lower due to hemodilution (total fluid and crystalloid 
      administration during CC, both P < .001), with premedication of acetylsalicylic 
      acid ( P = .014) and low-molecular-weight heparin ( P = .049). Arterial 
      thrombosis (3.85%), venous thrombosis (0.55%), and bleeding (1.65%) following CC 
      did not correlate with ACT values but occurred more frequently in children 
      between 1 month and 1 year of age (91%). In conclusion, with a bolus of 100 IU 
      UFH/kg, an ACT target level of 160 to 240 seconds can be achieved during CC in 
      children in 72%, which is influenced by hemodilution and anticoagulant and 
      antiplatelet premedication but not by age.
FAU - Muster, Ileana
AU  - Muster I
AD  - 1 Pediatric Cardiology, Pediatric Heart Center, University Children's Hospital 
      Zurich, Zurich, Switzerland.
AD  - 2 Children's Research Center, University Children's Hospital Zurich, Zurich, 
      Switzerland.
FAU - Haas, Thorsten
AU  - Haas T
AD  - 2 Children's Research Center, University Children's Hospital Zurich, Zurich, 
      Switzerland.
AD  - 3 Anesthesiology, University Children's Hospital Zurich, Zurich, Switzerland.
FAU - Quandt, Daniel
AU  - Quandt D
AD  - 1 Pediatric Cardiology, Pediatric Heart Center, University Children's Hospital 
      Zurich, Zurich, Switzerland.
AD  - 2 Children's Research Center, University Children's Hospital Zurich, Zurich, 
      Switzerland.
FAU - Kretschmar, Oliver
AU  - Kretschmar O
AD  - 1 Pediatric Cardiology, Pediatric Heart Center, University Children's Hospital 
      Zurich, Zurich, Switzerland.
AD  - 2 Children's Research Center, University Children's Hospital Zurich, Zurich, 
      Switzerland.
AD  - Oliver Kretschmar and Walter Knirsch contributed as senior authors.
FAU - Knirsch, Walter
AU  - Knirsch W
AD  - 1 Pediatric Cardiology, Pediatric Heart Center, University Children's Hospital 
      Zurich, Zurich, Switzerland.
AD  - 2 Children's Research Center, University Children's Hospital Zurich, Zurich, 
      Switzerland.
AD  - Oliver Kretschmar and Walter Knirsch contributed as senior authors.
LA  - eng
PT  - Journal Article
DEP - 20160811
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/therapeutic use
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests/*methods
MH  - Cardiac Catheterization/*adverse effects/*methods
MH  - Child
MH  - Child, Preschool
MH  - Hemodilution
MH  - Heparin/*administration & dosage
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Partial Thromboplastin Time
MH  - Premedication
MH  - Retrospective Studies
MH  - Thromboembolism/drug therapy/etiology/prevention & control
OTO - NOTNLM
OT  - anticoagulants
OT  - antiplatelet drugs
OT  - bleeding
OT  - cardiology
OT  - heparins
OT  - pediatric thrombosis
EDAT- 2016/08/16 06:00
MHDA- 2018/06/19 06:00
CRDT- 2016/08/13 06:00
PHST- 2016/08/16 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2016/08/13 06:00 [entrez]
AID - 1076029616660761 [pii]
AID - 10.1177/1076029616660761 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2017 Oct;23(7):740-747. doi: 10.1177/1076029616660761. 
      Epub 2016 Aug 11.